Evidence map›Paper›PMID 40474339›Full record

ArticleThe clinical respiratory journal2025

An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System.

Hang Chen, Yiming Shen, Yinyu Mu, Shuguang Xu, Shimo Shen, Weiyu Shen, Zeyang Hu, Hongxiang Li, Keyue Qiu, Jiaheng Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hang ChenDepartment of Thoracic Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang Province, China.
Yiming ShenDepartment of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, China.
Yinyu MuDepartment of Laboratory, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang Province, China.
Shuguang XuDepartment of Respiratory, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang Province, China.
Shimo ShenDepartment of Respiratory, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang Province, China.
Weiyu ShenDepartment of Thoracic Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang Province, China.
Zeyang HuMedical School, Ningbo University, Ningbo, Zhejiang Province, China.
Hongxiang LiMedical School, Ningbo University, Ningbo, Zhejiang Province, China.
Keyue QiuMedical School, Ningbo University, Ningbo, Zhejiang Province, China.
Jiaheng ZhangMedical School, Ningbo University, Ningbo, Zhejiang Province, China.
Zhe ChenDepartment of Thoracic Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang Province, China.
Guodong XuDepartment of Thoracic Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang Province, China.ORCID https://orcid.org/0000-0001-8684-6485

Funding

Basic Public Welfare Project of Ningbo 2019C50041Natural Science Foundation of Ningbo 2021J278Natural Science Foundation of Zhejiang LY22H160004Ningbo Clinical Research Center for Thoracic & Breast Neoplasms 2021L002Ningbo Health Technology Project 2022Y53Zhejiang Province Medical and Health Project 2022KY246
6 · The paper itself

Abstract

backgroundsPulmonary embolism (PE) is a common disease and a common cause of death. However, it is currently unclear which clinically common drugs can lead to PE.

methodsWe collected, organized, and analyzed reports from the first quarter of 2018 to the fourth quarter of 2022. We performed disproportionality analysis algorithms to calculate reporting odds ratio (ROR), which could quantify the signal values of different adverse events (AEs).

resultsWe have screened a total of 3091 drugs, with AE containing "PE" and calculated the ROR signal values of the top 30 drugs reported and ranked them. TESTIM (ROR = 32.03[28.77-35.66]), BARICITINIB (ROR = 23.48[20.55-26.83]), and NUVARIANG (ROR = 19.89[17.13-23.10]) are the drugs with the strongest correlation with PE. In addition, among the 30 drugs with the strongest correlation with PE, most of which are Biologics & Immunomodulators. Therefore, when using these 30 drugs, it is necessary to be alert to the possible risk of PE.

conclusionIn our study, we filtered 30 common drugs that could cause PE through the FAERS public database, which provides theoretical support for drug selection in the treatment of malignant tumors and IMID.

Indexed as

Adverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsPulmonary EmbolismUnited States Food and Drug AdministrationAlgorithmsHumansUnited Statesadverse eventsdrugsFDA adverse event reporting systemmolecular targeted agentspulmonary embolism

Identifiers

PMID40474339
PMCPMC12140972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.